SCHEMBL27218792

SCHEMBL27218792

NS(=O)(=O)c1ccc(SCc2nc(-c3ccc4c(c3)OCO4)no2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ PTGS1 P23219 3/20 0.44
▸ PTGS2 P35354 3/20 0.44
▸ MAPT P10636 3/20 0.41
▸ TSHR P16473 3/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ CHRM5 P08912 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218901 0.88 RAB9A (0.44) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL31494388 0.83 MAPT (0.54) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL31494452 0.83 MAPK1 (0.45) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL31494404 0.80 MAPT (0.44) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL31494450 0.77 MAPT (0.47) MAPTTSHRMAPK1SMN1; SMN2ALDH1A1
SCHEMBL27218716 0.74 SMN1; SMN2 (0.56) MAPTTSHRMAPK1SMN1; SMN2ALDH1A1
SCHEMBL31494432 0.74 GAA (0.53) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL31494445 0.74 CHRM2 (0.44) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL31494422 0.74 RAB9A (0.55) MAPTTSHRMAPK1POLBSMN1; SMN2
SCHEMBL27218787 0.73 RAB9A (0.54) MAPTTSHRMAPK1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 CA12 4505/4885CA2 3506/4885CA9 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback